.Attribute Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for introduction of people with MASLD and measurement of liver results in cardio-- renal-- metabolic trials, when records suggest mechanistically plausible advantages and clinical protection-- as well as describes factors for test style and regulatory commendation.